Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O Vesterqvist

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Cardiovascular Research|June 1, 1996
Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit heartsO Vesterqvist, C A Sargent, G J Grover, et al.
Prostaglandins|October 1, 1982
Plasma levels of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 in connection with its development as an abortifacientK Gréen, O Vesterqvist, M Bygdeman, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|August 1, 1988
Development of a vaginal gel containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 for cervical dilatation and pregnancy terminationK Gréen, M Bygdeman, M L Swahn, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancerP Henriksson, M Blombäck, G Bratt, et al.
Journal of Lipid Research|July 1, 1993
Peroxisomal chain-shortening of thromboxane B2: evidence for impaired degradation of thromboxane B2 in Zellweger syndromeU Diczfalusy, O Vesterqvist, B F Kase, et al.
Journal of Internal Medicine|July 1, 1993
Plasma growth factor activity and cardiac wall thicknessC Lemne, S Volk-Jovinge, J Nilsson, et al.
Journal of Clinical Pharmacology|January 5, 2002
Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemideH Uderman, O Vesterqvist, J Manning, et al.
Prostaglandins|September 1, 1992
Platelet activation and prostacyclin release in essential hypertensionC Lemne, O Vesterqvist, N Egberg, et al.
Clinical Pharmacology and Therapeutics|May 1, 1999
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansC Massien, M Azizi, T T Guyene, et al.
European Journal of Clinical Pharmacology|August 11, 2001
Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokineticsP O'Grady, O Vesterqvist, B Malhotra, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Cardiovascular Research|June 1, 1996
Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit heartsO Vesterqvist, C A Sargent, G J Grover, et al.
Prostaglandins|October 1, 1982
Plasma levels of 9-deoxo-16,16-dimethyl-9-methylene-PGE2 in connection with its development as an abortifacientK Gréen, O Vesterqvist, M Bygdeman, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|August 1, 1988
Development of a vaginal gel containing 9-deoxo-16,16-dimethyl-9-methylene PGE2 for cervical dilatation and pregnancy terminationK Gréen, M Bygdeman, M L Swahn, et al.
Medical Oncology and Tumor Pharmacotherapy|January 1, 1989
Effects of oestrogen therapy and orchidectomy on coagulation and prostanoid synthesis in patients with prostatic cancerP Henriksson, M Blombäck, G Bratt, et al.
Journal of Lipid Research|July 1, 1993
Peroxisomal chain-shortening of thromboxane B2: evidence for impaired degradation of thromboxane B2 in Zellweger syndromeU Diczfalusy, O Vesterqvist, B F Kase, et al.
Journal of Internal Medicine|July 1, 1993
Plasma growth factor activity and cardiac wall thicknessC Lemne, S Volk-Jovinge, J Nilsson, et al.
Journal of Clinical Pharmacology|January 5, 2002
Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemideH Uderman, O Vesterqvist, J Manning, et al.
Prostaglandins|September 1, 1992
Platelet activation and prostacyclin release in essential hypertensionC Lemne, O Vesterqvist, N Egberg, et al.
Clinical Pharmacology and Therapeutics|May 1, 1999
Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humansC Massien, M Azizi, T T Guyene, et al.
European Journal of Clinical Pharmacology|August 11, 2001
Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokineticsP O'Grady, O Vesterqvist, B Malhotra, et al.
Pageof 6